Management in Patients with Fabry Disease.

Practical Guidance based on the 2022 ADA/EASD Guidelines.

PRALUENT^®: a PCSK9i that ticks all the boxes^1–4

PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.² It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.² Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.¹

Know the signs and symptoms of acquired TTP (aTTP).

Early diagnosis and treatment of Thrombotic thrombocytopenic purpura (TTP) can help prevent the high risk of early deaths.